Report of Foreign Issuer (6-k)
September 08 2016 - 8:33AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to
Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of September 2016
001-36345
(Commission File Number)
GALMED PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in its
charter)
16 Tiomkin St.
Tel Aviv 6578317, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F
☒
Form 40-F
☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
On September
8, 2016, Galmed Pharmaceuticals Ltd. (the “Company”) announced the appointment of Dr. Liat Hayardeny, Ph.D., MBA, as
Chief Scientific Officer, effective as of September 7, 2016. A copy of the press release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.
This Form 6-K is incorporated by reference into the Company's
Registration Statement on Form S-8 filed with the Securities and Exchange Commission on August 11, 2015 (Registration No. 333-206292)
and its Registration Statement on Form F-3 filed with the Securities and Exchange Commission on March 31, 2015 (Registration No.
333- 203133).
The information contained herein may not be copied, adapted
or distributed and is not warranted to be accurate, complete or timely. The user assumes all risks for any damages or losses arising
from any use of this information, except to the extent such damages or losses cannot be limited or excluded by applicable law.
Past financial performance is no guarantee of future results.
Exhibit Index
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated September 8, 2016
|
The information contained herein may not be copied, adapted
or distributed and is not warranted to be accurate, complete or timely. The user assumes all risks for any damages or losses arising
from any use of this information, except to the extent such damages or losses cannot be limited or excluded by applicable law.
Past financial performance is no guarantee of future results.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Galmed Pharmaceuticals Ltd.
|
|
|
Date: September 8, 2016
|
By:
|
/s/ Allen Baharaff
|
|
|
Allen Baharaff
|
|
|
President and Chief Executive Officer
|
The information contained herein may not be copied, adapted
or distributed and is not warranted to be accurate, complete or timely. The user assumes all risks for any damages or losses arising
from any use of this information, except to the extent such damages or losses cannot be limited or excluded by applicable law.
Past financial performance is no guarantee of future results.
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Apr 2023 to Apr 2024